Big Pharma drug clears regulatory hurdle

|By:, SA News Editor

The FDA approves Bristol-Myers Squibb (BMY) and Pfizer's (PFE) sNDA for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis for patients who have undergone knee or hip replacement surgery.

In the U.S., 719,000 knee replacement and 332,000 hip replacement surgeries are performed each year.

The product is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.